“This is an exciting new application of a known medication that, in addition to potentially protecting and/or expanding the beta cells that remain in early type 1 diabetes patients, might also be able to help other patients with diabetes to increase beta cell number and/or function,” said Fouad R. Kandeel, M.D., Ph.D., the Arthur D. Riggs Distinguished Chair in Diabetes & Metabolism Research at City of Hope and the trial’s co-principal investigator. “We are actively working to enroll qualified patients and look forward to seeing where this trial leads us.”